Core B - David Elder The Pathology Core is responsible for the provision of expert pathological assistance in the interpretation of histological data to the Projects, for the development of immunohistochemical and in situ hybridization methods to enable the identification of antigens or mRNAs in archival and freshly-isolated tissues, and for accrual of residual material not required for diagnosis from human melanomas and nevi for use in the Projects. Expertise in all aspects of the pathological diagnosis and classification of melanocytic neoplasms is provided to the projects on a continuing basis, and is useful in the characterization of experimental models, as well as in the evaluation of expression of novel and experimental markers in benign, intermediate, and malignant melanocytic tumors. The Core personnel are expert in standard immunohistochemical and in situ hybridization techniques, and are very experienced in the workup of novel antibodies and probes. Under previous funding, the Core has been continuously involved in the procurement, prioritization, and provision of tissue, blood, and other biological samples for research projects. Appropriate IRB approved informed consent protocols are used. The Core maintains a shared bank of frozen tissue, and of paraffin blocks and/or sections, from melanocytic tumors, The Core has participated in the production of two tissue microarrays with cooperative groups and has access to slides from these. In addition, the Core is involved in an ongoing basis in the continuing accrual of tissues. These functions are shared with other programs, providing efficiencies that allow this Core to provide a much wider arrange of services and procurement functions than might otherwise be feasible. Biosamples are prioritized through a Tissue Allocation Committee that includes investigators from this program project, as well as from other programs. In this manner, collection, initial processing, storage if necessary, prioritization, distribution, and usage of material in the projects can be reliably tracked and optimized to ensure the best use of scarce tissue resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA114046-03
Application #
8082800
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
3
Fiscal Year
2010
Total Cost
$177,285
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ojha, Rani; Leli, Nektaria M; Onorati, Angelique et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504
Nti, Akosua A; Serrano, Leona W; Sandhu, Harpal S et al. (2018) FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina :
Perego, M; Maurer, M; Wang, J X et al. (2018) A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene 37:302-312
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Hammerlindl, Heinz; Ravindran Menon, Dinoop; Hammerlindl, Sabrina et al. (2018) Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. Clin Cancer Res 24:1090-1102
Ecker, Brett L; Kaur, Amanpreet; Douglass, Stephen M et al. (2018) Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. Cancer Discov :
Cañadas, Israel; Thummalapalli, Rohit; Kim, Jong Wook et al. (2018) Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24:1143-1150
Grasso, Michael; Estrada, Michelle A; Berrios, Kiara N et al. (2018) N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers. J Med Chem 61:5034-5046

Showing the most recent 10 out of 144 publications